MYC and pancreatic neoplasm: Combining the bromodomain inhibitor JQ1 with the histone deacetylase inhibitor SAHA in pancreatic cancer inhibits both MYC activity and inflammatory signals as well as in an established adenocarcinoma lung cancer model with KRasG12D mutation and p53 loss [36].